Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease

doi:10.1016/j.cgh.2016.01.016

Clinical Gastroenterology and Hepatology

Volume 14, Issue 6, June 2016, Pages 818-824.e6

https://doi.org/10.1016/j.cgh.2016.01.016 Get rights and content

Background & Aims

There is evidence that immune dysfunction precedes symptoms of inflammatory bowel disease (IBD) by several years. Characterization of preclinical systemic inflammation could contribute to the understanding of the biology of IBD and, ultimately, facilitate development of strategies for early disease detection and intervention. We evaluated associations between circulating levels of interleukin-6 (IL6) and high-sensitivity C-reactive protein (hsCRP) and diagnosis of incident Crohn’s disease (CD) or ulcerative colitis (UC).

Methods

We conducted a nested case-control study of participants enrolled in 2 population-based, nationwide, prospective cohort studies (the Nurses’ Health Study and the Nurses’ Health Study II). We analyzed blood specimens, collected before diagnosis, from 83 persons with CD, 90 persons with UC, and 344 matched individuals without IBD (control subjects). Plasma levels of hsCRP and IL6 were measured. We investigated associations between each inflammatory marker and IBD risk using multivariable logistic regression models to adjust for potential confounding exposures.

Results

Compared with the lowest quintile of IL6 level, the highest quintile was associated with an odds ratio (OR) of 4.68 (95% confidence interval, 1.91–11.46) for CD (P_trend < .001) and an OR of 3.43 (95% confidence interval, 1.44–8.15) for UC (P_trend = .004). The highest quintile of hsCRP level, compared with the lowest quintile, was associated with an OR of 2.82 (95% confidence interval, 1.15–6.87) for CD (P_trend = .019) and an OR of 1.79 (95% confidence interval, 0.80–3.99) for UC (P_trend = .015).

Conclusions

Plasma levels of IL6 and hsCRP before diagnosis are associated with risk of incident CD and UC. Subclinical levels of systemic inflammation may be a feature of an early disease state that precedes the development of symptomatic IBD.

Section snippets

Study Populations

The NHS is a nationwide prospective cohort that was initiated in 1976 with the enrollment of 121,700 female registered nurses, aged 30–55 years, who had completed a postal health questionnaire. Follow-up questionnaires have been mailed every 2 years to update health and lifestyle information. The Nurses’ Health Study II (NHSII) is a parallel cohort established in 1989 with the enrollment of 116,686 female nurses, aged 25–42 years. Women in the NHSII have been followed up similarly, by means of

Results

The median time interval between blood collection and diagnosis of CD or UC was 6.6 and 6.8 years, respectively (range, 1 month to 20.4 years). The age range of participants at the time of blood sampling was 35–69 years. Characteristics of cases and control subjects at the time of blood collection are shown in Table 1. Cases and control subjects did not differ significantly with respect to age, BMI, physical activity, menopausal status, or exogenous hormone use (OC or MHT). Compared with

Discussion

In our nested case-control study, conducted within 2 U.S. nationwide prospective cohorts, we found that prediagnostic circulating levels of IL6 and hsCRP were associated with the risk of CD and UC. These observations suggest that subclinical inflammation may be a feature of a predisease state in IBD. Preclinical disease phases, defined by positive serologic markers in the absence of symptoms, have been described for other immune-mediated inflammatory disorders, such as rheumatoid arthritis⁵ and

Acknowledgments

The authors thank Dr Nader Rifai, and Gary Bradwin of Boston Children’s Hospital for their assistance with measurement of plasma inflammatory markers. The authors are indebted to the participants of the Nurses’ Health Study and the Nurses’ Health Study II.

References (29)

K.D. Deane et al.
Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation
Rheum Dis Clin North Am
(2010)
E.V. Loftus et al.
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival
Gastroenterology
(1998)
G. Kenis et al.
Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum
Cytokine
(2002)
A.P. Doumatey et al.
High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum
Clin Biochem
(2014)
D.J. Hunter et al.
Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women
Contraception
(1997)
J.M. Robertson et al.
Preclinical systemic lupus erythematosus
Rheum Dis Clin North Am
(2014)
R.S. Choung et al.
Longitudinal status of serological markers predict Crohn's disease phenotype before diagnosis: a ‘PREDICTS’ study
Gastroenterology
(2015)
N. Powell et al.
Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation
Gastroenterology
(2015)
M.J. Waldner et al.
Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development
Semin Immunol
(2014)
M.D. Kappelman et al.
Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population
Dig Dis Sci
(2013)

B. Khor et al.

Genetics and pathogenesis of inflammatory bowel disease

Nature

(2011)

E. Israeli et al.

Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease

Gut

(2005)

F.D. van Schaik et al.

Serological markers predict inflammatory bowel disease years before the diagnosis

Gut

(2013)

E.W. Karlson et al.

Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies

Arthritis Rheum

(2009)

Cited by (57)

Preclinical Serological Signatures are Associated With Complicated Crohn's Disease Phenotype at Diagnosis
2023, Clinical Gastroenterology and Hepatology
At diagnosis, up to one-third of patients with Crohn’s disease (CD) have a complicated phenotype with stricturing (B2) or penetrating (B3) behavior or require early surgery. We evaluated protein biomarkers and antimicrobial antibodies in serum archived years before CD diagnosis to assess whether complicated diagnoses were associated with a specific serological signature.
Prediagnosis serum was obtained from 201 patients with CD and 201 healthy controls. Samples were evaluated with a comprehensive panel of 1129 proteomic markers (SomaLogic) and antimicrobial antibodies. CD diagnosis and complications were defined by the International Classification of Diseases–Ninth Revision and Current Procedural Terminology codes. Cox regression models were utilized to assess the association between markers and the subsequent risk of being diagnosed with complicated CD. In addition, biological pathway and network analyses were performed.
Forty-seven CD subjects (24%) had a B2 (n = 36) or B3 (n = 9) phenotype or CD-related surgery (n = 2) at diagnosis. Subjects presenting with complicated CD at diagnosis had higher levels of antimicrobial antibodies six years before diagnosis as compared with those diagnosed with noncomplicated CD. Twenty-two protein biomarkers (reflecting inflammatory, fibrosis, and tissue protection markers) were found to be associated with complicated CD. Pathway analysis of the altered protein biomarkers identified higher activation of the innate immune system and complement or coagulation cascades up to six years before diagnosis in complicated CD.
Proteins and antimicrobial antibodies associated with dysregulated innate immunity, excessive adaptive response to microbial antigens, and fibrosis precede and predict a complicated phenotype at the time of diagnosis in CD patients.
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis
2023, Gastroenterology
Better biomarkers for prediction of ulcerative colitis (UC) development and prognostication are needed. Anti-integrin αvβ6 (anti-αvβ6) autoantibodies have been described in patients with UC. We tested for the presence of anti-αvβ6 antibodies in the preclinical phase of UC and studied their association with disease-related outcomes after diagnosis.
Anti-αvβ6 autoantibodies were measured in 4 longitudinal serum samples collected from 82 subjects who later developed UC and 82 matched controls from a Department of Defense preclinical cohort (PREDICTS [Proteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects]). In a distinct, external validation cohort (Crohn’s and Colitis Canada Genetic Environmental Microbial project cohort), we tested 12 pre-UC subjects and 49 matched controls. Furthermore, anti-αvβ6 autoantibodies were measured in 2 incident UC cohorts (COMPASS [Comprehensive Care for the Recently Diagnosed IBD Patients], n = 55 and OSCCAR [Ocean State Crohn's and Colitis Area Registry], n = 104) and associations between anti-αvβ6 autoantibodies and UC-related outcomes were defined using Cox proportional hazards model.
Anti-αvβ6 autoantibodies were significantly higher among individuals who developed UC compared with controls up to 10 years before diagnosis in PREDICTS. The anti-αvβ6 autoantibody seropositivity was 12.2% 10 years before diagnosis and increased to 52.4% at the time of diagnosis in subjects who developed UC compared with 2.7% in controls across the 4 time points. Anti-αvβ6 autoantibodies predicted UC development with an area under the curve of at least 0.8 up to 10 years before diagnosis. The presence of anti-αvβ6 autoantibodies in preclinical UC samples was validated in the GEM cohort. Finally, high anti-αvβ6 autoantibodies was associated with a composite of adverse UC outcomes, including hospitalization, disease extension, colectomy, systemic steroid use, and/or escalation to biologic therapy in recently diagnosed UC.
Anti-integrin αvβ6 autoantibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes.
Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses’ Health Study cohorts
2022, Environmental Research
Perfluoroalkyl substances (PFASs) are synthetic compounds used in a wide variety of industrial and consumer applications. An association between PFAS exposure and risk of ulcerative colitis (UC) has been reported in a highly exposed population. However, data are limited on risk of inflammatory bowel diseases (IBD) among individuals with background population levels of PFAS exposure.
We set out to examine the association between plasma PFAS concentrations and risk of IBD among women in two population-based, prospective cohort studies in which pre-diagnostic blood specimens were available.
We conducted a nested case-control study in the Nurses' Health Study and Nurses' Health Study II cohorts. We identified 73 participants with incident Crohn's disease (CD) and 80 participants with incident UC who had provided blood samples before diagnosis. Cases were matched 1:2 to IBD-free controls. Plasma concentrations of five major PFASs were measured by liquid chromatography and tandem mass spectrometry. We used conditional logistic models to estimated odds ratios for risk of IBD according to log₁₀-transformed PFAS concentrations, adjusting for potential confounders.
In multivariable models, we observed inverse associations between plasma concentrations of three PFASs and risk of CD (all P ≤ 0.012 for a standard deviation increase in log₁₀PFAS). The inverse association with CD was strongest for perfluorodecanoate, where, compared to the lowest tertile, the odds ratio (OR) for the highest tertile was 0.39 (95% confidence interval, 0.17–0.92). No associations were observed between PFAS concentrations and UC risk.
Our results do not support the hypothesis that elevated PFAS exposure is associated with higher risk of UC. Contrary to expectation, our data suggest that circulating concentrations of some PFASs may be inversely associated with CD development.
Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
2022, Gastroenterology
Despite improved therapeutic strategies and expanding therapeutic targets, inflammatory bowel disease remains a disabling disease with potential to progress and lead to irreversible complications. Increased evidence supports the concept of a preclinical phase in inflammatory bowel disease, preceding clinical diagnosis, during which immune and inflammatory pathways are already altered. As knowledge about this prediagnosis period expands, it unlocks the possibility of disease prediction and ambition for disease prevention and interception. Targeting the early pathogenic events that promote the development of inflammatory bowel disease could prevent or attenuate disease onset and offer a true opportunity for disease modification.
Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay
2022, Clinical Biochemistry
Citation Excerpt :
The assay could meet clinical requirements with recovery rates of 97.6%, 100.7%, and 100.9%, respectively (Supplementary Table 3). IL-6 and IL-18, which also belong to the IL-6 family, have been proved to be associated with the risk of IBD and clinical response [17–19]. In the assessment of cross-reactivities, OSM standards (500 pg/mL) were diluted with five concentration gradients of IL-6 (40, 93, 146, 199, and 252 pg/mL) and IL-18 solutions (50, 150, 500, 1000, and 1500 pg/mL) and were tested repeatedly three times.
Although endoscopy is the gold standard to assess disease activity and infliximab efficacy in inflammatory bowel disease (IBD), the invasive, costly, and time-consuming procedure limits its routine applications. We aimed to investigate the clinical value of serum oncostatin M (OSM) as a surrogate biomarker.
Fifty healthy controls, 34 non-IBD patients, and 189 IBD patients who were pre-infliximab treatment (n = 122) or in infliximab maintenance (n = 67) were enrolled. A chemiluminescence immunoassay (CLIA) was constructed to quantify serum OSM concentrations. Receiver operator characteristic (ROC) curve analysis was used to evaluate the performance of blood biomarkers for IBD management.
The methodology of CLIA exhibited great analytical performance with a wide linear range of 31.25–25000 pg/mL, a low detection limit of 23.2 pg/mL, acceptable precision, and applicable accuracy. Patients with IBD (121.5 [43.3–249.4] pg/mL, p < 0.001) and non-IBD (72.4 [51.4–129.6] pg/mL, p = 0.005) had higher serum OSM levels than healthy controls (35.8 [23.2–56.4] pg/mL). In the analysis of clinical and endoscopic activity, serum OSM levels were elevated in moderate and severe patients compared to those in remission. IBD patients without mucosal healing had higher serum OSM levels than those with mucosal healing (AUC = 0.843). Besides, serum OSM levels were increased in clinical non-responders (287.3 [127.9–438] pg/mL) compared to responders (24.1 [23.2–53.4] pg/mL, p < 0.001), and showed great recognition ability with an AUC of 0.898.
The newly developed methodology of CLIA had great potential for use in the clinic. Elevated serum OSM expression was a promising biomarker of severe disease and infliximab non-response in IBD patients.
Systemic Inflammation in Preclinical Ulcerative Colitis
2021, Gastroenterology
Citation Excerpt :
The study design, in which controls to cases with preclinical ulcerative colitis were matched by sex, age, and time of sampling, reduces the influence of bias due to potential differences in demographics. The inclusion criteria were similar to those used in the European Prospective Investigation Into Cancer and Nutrition study and Nurses’ Health Study cohorts,8,9 resulting in a study population with relatively high ages at diagnosis, which can potentially limit the possibility to generalize the findings to all patients with ulcerative colitis. Old-onset IBD has been associated with a longer doctor and patient delay, that is, presence of symptoms long before diagnosis compared with younger peers.52
Preclinical ulcerative colitis is poorly defined. We aimed to characterize the preclinical systemic inflammation in ulcerative colitis, using a comprehensive set of proteins.
We obtained plasma samples biobanked from individuals who developed ulcerative colitis later in life (n = 72) and matched healthy controls (n = 140) within a population-based screening cohort. We measured 92 proteins related to inflammation using a proximity extension assay. The biologic relevance of these findings was validated in an inception cohort of patients with ulcerative colitis (n = 101) and healthy controls (n = 50). To examine the influence of genetic and environmental factors on these markers, a cohort of healthy twin siblings of patients with ulcerative colitis (n = 41) and matched healthy controls (n = 37) were explored.
Six proteins (MMP10, CXCL9, CCL11, SLAMF1, CXCL11 and MCP-1) were up-regulated (P < .05) in preclinical ulcerative colitis compared with controls based on both univariate and multivariable models. Ingenuity Pathway Analyses identified several potential key regulators, including interleukin-1β, tumor necrosis factor, interferon-gamma, oncostatin M, nuclear factor-κB, interleukin-6, and interleukin-4. For validation, we built a multivariable model to predict disease in the inception cohort. The model discriminated treatment-naïve patients with ulcerative colitis from controls with leave-one-out cross-validation (area under the curve = 0.92). Consistently, MMP10, CXCL9, CXCL11, and MCP-1, but not CCL11 and SLAMF1, were significantly up-regulated among the healthy twin siblings, even though their relative abundances seemed higher in incident ulcerative colitis.
A set of inflammatory proteins are up-regulated several years before a diagnosis of ulcerative colitis. These proteins were highly predictive of an ulcerative colitis diagnosis, and some seemed to be up-regulated already at exposure to genetic and environmental risk factors.

View all citing articles on Scopus

: Conflicts of interest These authors disclose the following: Ashwin Ananthakrishnan is a member of the scientific advisory board for Exact Sciences, Abbvie, and Cubist Pharmaceuticals. James Richter is a consultant for Policy Analysis. Andrew Chan has served as a consultant for Bayer Healthcare, Pfizer, and Pozen. The remaining authors disclose no conflicts.

: Funding This study was supported by grants UM1 CA186107, R01 CA49449, UM1 CA176726, R01 CA67262, and K24 DK098311 from the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Chan is supported by a senior investigator award from the Crohn’s and Colitis Foundation of America. Dr Khalili is supported by a career development award from the American Gastroenterological Association and by the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK099681). Dr. Ananthakrishnan is supported by the National Institute of Health (K23 DK091742). The funders had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; nor in the preparation, review, and approval of the manuscript.

View full text

Original articleAlimentary tractAssociation Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease

Background & Aims

Methods

Results

Conclusions

Section snippets

Study Populations

Results

Discussion

Acknowledgments

Rheum Dis Clin North Am

Gastroenterology

Cytokine

Clin Biochem

Contraception

Rheum Dis Clin North Am

Gastroenterology

Gastroenterology

Semin Immunol

Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population

Dig Dis Sci

Genetics and pathogenesis of inflammatory bowel disease

Nature

Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease

Gut

Serological markers predict inflammatory bowel disease years before the diagnosis

Gut

Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies

Arthritis Rheum

Original article
Alimentary tract
Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease